The company provides doctors with critical AI-driven patient insights to aide their clinical decision-making and optimise clinic workflow and efficiency, increasing daily treatments while maintaining the same level of high quality of care.

“The fertility market is growing at an unprecedented rate and becoming a pressing issue on a global scale,” said Raissa Hacohen, Managing Partner of Longevity Venture Partners. “We invested in FertilAI because the team's expertise is uniquely suited to solve this market need and its platform has already demonstrated significant traction in the market.”

FertilAI focuses on making fertility treatments easier and more effective for everyone. In 2024 alone, the product is being used globally by more than 50 physicians across 20,000+ patients.

The AI-based Fertilane platform seamlessly integrates with clinic electronic medical records (EMRs) to improve predictability, clinical outcomes, and the patient experience throughout the fertility journey, from identifying optimal embryo transfer timing and optimising decision-making throughout the stimulation cycle to ovulation tracking, supporting timed intercourse, and facilitating intrauterine insemination (IUI). Furthermore, the mobile patient app improves two-way communication between clinic and patients.

“We are absolutely delighted to support Rohi and his Tier 1 team on their mission to tangibly improve clinical outcomes with FertilAI’s next-generation algorithm,” said Helena Cavell, Principal at Redseed.

Offered as a unified platform, Fertilane provides physicians with a single address for individual patients, their treatment plans and recommendations, and all clinic-doctor-patient communications

“The investment is a significant validation of our mission and vision,” said Rohi Hourvitz, CEO of FertilAI. “Everything we do is focused on providing the opportunity to create families more quickly and affordably. We want patients to achieve pregnancy much earlier in the process, instead of struggling through multiple rounds of treatment at thousands of dollars each.”

The $4.5 million seed round will be invested in market expansion, personnel, and reinforcing R&D efforts, allowing the company to deliver solutions for better patient care throughout the entire fertility journey.